First-ever C. difficile protection for the billions of patients on antibiotic therapy.

digital graphic of inflammatory bowel disease

Watch a video about antibiotics and C. difficile colitis HERE.

While antibiotic therapy is the foundation of modern medicine, it also is the number one cause of a potentially deadly superinfection called C. difficile colitis.

LPOXY Therapeutics is developing a pill that taken with antibiotics gently increases the colon’s oxygen tension and prevents antibiotic-induced C. difficile colitis via three mechanisms.

The LPOXY team is driven to protect people from this deadly antibiotic-induced superinfection.

  • The Centers for Disease Control and Prevention considers C. difficile colitis an URGENT
    public health threat.

  • C. difficile colitis afflicts nearly a half million Americans each year.

  • Thirty thousand will die.

  • And there are no therapies or vaccines to prevent this antibiotic-induced superinfection.

SIDIFENS orally-administered, metered-dose intestinal oxygen delivery is being developed for multiple indications

  • Antibiotic-induced C. difficile colitis superinfection prevention

    • Oxygen’s clinical effectiveness established in humans

  • Ulcerative colitis

    • Oxygen’s clinical effectiveness established in humans

  • Crohn’s diseases

    • Oxygen’s clinical effectiveness established in humans

  • Multiple sclerosis

    • Via oxygen’s effectiveness vs epsilon-toxin-producing C. perfringens

  • Neuromyelitis optica

    • Via oxygen’s effectiveness vs epsilon-toxin-producing C. perfringens

For more information reach out.

Click HERE to follow our equity crowdfunding campaign